Dapagliflozin

CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.

Endocrine Today has compiled a list of breaking drug trial news reports posted from the annual meeting of the European Association for the Study of Diabetes Annual Meeting.

The FDA recently approved the first oral GLP-1 receptor agonist for diabetes and granted fast track designation to dapagliflozin for worsening heart failure — these were among the top endocrinology stories last week.

Many of the top stories in cardiology last week were from Healio’s live coverage of the Heart Failure Society of America’s Scientific Meeting. They included an interview with retired basketball star Shaq, who discusses how a new campaign intends to raise awareness of heart failure in blacks.

PHILADELPHIA — In patients with HF with reduced ejection fraction with or without diabetes, the SGLT2 inhibitor dapagliflozin was associated with clinically meaningful improvements in HF-related health status or N-terminal pro-B type natriuretic peptide at 12 weeks, according to results of the DEFINE-HF trial presented at the Heart Failure Society of America Scientific Meeting.

The FDA has granted fast track designation to the SGLT2 inhibitor dapagliflozin for reducing the risk for cardiovascular death or worsening heart failure among adults with heart failure with reduced or preserved ejection fraction, according to a press release from AstraZeneca.

PARIS — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy in patients with HF with reduced ejection fraction, regardless of diabetes status, according to results of the DAPA-HF trial.